Patents by Inventor Thomas LANGENICKEL

Thomas LANGENICKEL has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • USE OF IFN-LAMBDA MRNA FOR TREATING VIRAL INFECTIONS
    Publication number: 20240181011
    Abstract: The present invention relates to pharmaceutical compositions comprising an mRNA encoding an IFN-? polypeptide for use in treating a viral-induced disorder, preferably a viral-induced respiratory disorder, such as COVID-19.
    Type: Application
    Filed: November 4, 2021
    Publication date: June 6, 2024
    Inventors: Carsten Rudolph, Christian Plank, Thomas Langenickel, Anna Macht, Kristin Lohmer
  • Pyridine and Pyrazine derivative for the Treatment of CF, COPD, and Bronchiectasis
    Publication number: 20240058315
    Abstract: The present invention provides pyridine and pyrazine derivatives which restore or enhance the function of mutant and/or wild type CFTR to treat bronchiectasis, cystic fibrosis, primary ciliary dyskinesia, chronic bronchitis, chronic obstructive pulmonary disease, asthma, respiratory tract infections, lung carcinoma, xerostomia and keratoconjunctivitis sire, or constipation (IBS, IBD, opioid induced). Pharmaceutical compositions comprising such derivatives are also encompassed.
    Type: Application
    Filed: August 8, 2023
    Publication date: February 22, 2024
    Inventors: Sarah Schmidt GRANT, Bettina HEDERER, Thomas LANGENICKEL, David J. ROWLANDS, Robert Martin STRIETER, Xianbin TIAN
  • Pyridine and Pyrazine derivative for the Treatment of CF, COPD, and Bronchiectasis
    Publication number: 20200383960
    Abstract: The present invention provides pyridine and pyrazine derivatives which restore or enhance the function of mutant and/or wild type CFTR to treat bronchiectasis, cystic fibrosis, primary ciliary dyskinesia, chronic bronchitis, chronic obstructive pulmonary disease, asthma, respiratory tract infections, lung carcinoma, xerostomia and keratoconjunctivitis sire, or constipation (IBS, IBD, opioid induced). Pharmaceutical compositions comprising such derivatives are also encompassed.
    Type: Application
    Filed: June 8, 2020
    Publication date: December 10, 2020
    Inventors: Sarah Schmidt GRANT, Bettina HEDERER, Thomas LANGENICKEL, David J. ROWLANDS, Robert Martin STRIETER, Xianbin TIAN
  • SACUBITRIL AND VALSARTAN FOR TREATING METABOLIC DISEASE
    Publication number: 20180140579
    Abstract: The present invention relates to methods and pharmaceutical compositions for prevention or treatment of a metabolic disease in a human patient in need thereof, comprising administration of a therapeutically effective amount, or a prophylactically effective amount, of a combination of sacubitril and valsartan in a 1:1 molar ratio to said patient.
    Type: Application
    Filed: May 27, 2016
    Publication date: May 24, 2018
    Inventors: Diego ALBRECHT, Thomas LANGENICKEL, Jens JORDAN, Stefan ENGELI
  • New Use
    Publication number: 20160206597
    Abstract: The present invention relates to methods and pharmaceutical compositions for renal protection in a mammal in need thereof, such as a mammal having a disease manifested by atrial enlargement and/or remodeling or suffering from hypertension or heart failure or being prone to suffering from hypertension and/or heart failure, comprising administration of a therapeutically effective amount, or a prophylactically effective amount, of an Angiotensin Receptor Neprilysin inhibitor (ARNi) or of a combination of an Angiotensin Receptor Blocker (ARB) with a Neutral Endopeptidase inhibitor (NEPi) or with a NEPi pro-drug to said mammal.
    Type: Application
    Filed: August 26, 2013
    Publication date: July 21, 2016
    Inventors: Toni Lynne Bransford, Bryan BURKEY, Thomas LANGENICKEL, Martin LEFKOWITZ, Victor Chengwei SHI